Ratings by Maxim Group (Naureen Quibria)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/13/2026 | Immutep Limited | IMMP | Downgrade | Hold (Buy) |
2.76 (0.39) |
-85.87% | Details | |
| 4/4/2023 | Oncternal Therapeutics | ONCT | Downgrade | Hold (Buy) |
0.79 (0.53) |
-32.91% | Details | |
| 9/29/2022 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2022 | Kazia Therapeutics | KZIA | Downgrade | Hold (Buy) |
3.63 (14.69) |
304.68% | Details | |
| 3/10/2022 | Oncorus Inc. | ONCR | Maintain | Buy (N/A) |
|
Details | ||
| 2/25/2022 | Cardiff Oncology | CRDF | Maintain | Buy (N/A) |
|
Details | ||
| 1/13/2022 | Genenta Science S.p.A. | GNTA | New Coverage | Buy (N/A) |
9.94 (1.84) |
-81.49% | Details | |
| 12/20/2021 | Ayala Pharmaceuticals | AYLA | New Coverage | Buy (N/A) |
9.03 (0.50) |
-94.46% | Details | |
| 11/30/2021 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Buy (N/A) |
|
Details | ||
| 11/16/2021 | Oncorus Inc. | ONCR | Maintain | Buy (N/A) |
|
Details | ||
| 11/15/2021 | Medicenna Therapeutics | MDNA | Maintain | Buy (N/A) |
|
Details | ||
| 10/14/2021 | Kazia Therapeutics | KZIA | New Coverage | Buy (N/A) |
10.61 (14.69) |
38.45% | Details | |
| 9/9/2021 | Cardiff Oncology | CRDF | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2021 | Cardiff Oncology | CRDF | New Coverage | Buy (N/A) |
5.76 (1.25) |
-78.3% | Details | |
| 7/16/2021 | Immutep Limited | IMMP | New Coverage | Buy (N/A) |
3.53 (2.76) |
-21.81% | Details |
